Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LRP1Bmutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
Landon C. Brown, Matthew D. Tucker, Ramy Sedhom, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001792-e001792
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

A whole-slide foundation model for digital pathology from real-world data
Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, et al.
Nature (2024) Vol. 630, Iss. 8015, pp. 181-188
Open Access | Times Cited: 108
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma
Alexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
JAMA Oncology (2022)
Open Access | Times Cited: 46
A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma
Jie Peng, Dan Zou, Xudong Zhang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer
Yingjie Li, Chaohu Pan, Yuye Gao, et al.
JAMA Surgery (2024) Vol. 159, Iss. 5, pp. 529-529
Closed Access | Times Cited: 9
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie R. Bhandare, Sai H. S. Boddu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116275-116275
Open Access | Times Cited: 9
LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance
Xiangyu Zhai, Zhijia Xia, Gang Du, et al.
Genes & Diseases (2022) Vol. 10, Iss. 5, pp. 2082-2096
Open Access | Times Cited: 38
Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma
Jui Wan Loh, Jing Yi Lee, Abner Herbert Lim, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 17
A whole-genome scan for evidence of recent positive and balancing selection in aye-ayes (Daubentonia madagascariensis) utilizing a well-fit evolutionary baseline model
Vivak Soni, John W. Terbot, Cyril J. Versoza, et al.
(2024)
Open Access | Times Cited: 8
LRP1B: A Giant Lost in Cancer Translation
Catarina Príncipe, Isabel Sousa, Hugo Prazeres, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 836-836
Open Access | Times Cited: 41
MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy.
Taylor E. Arnoff, Wafik S. El‐Deiry
PubMed (2022) Vol. 12, Iss. 5, pp. 2102-2117
Closed Access | Times Cited: 20
Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy
Mingyu Zhu, Lu Zhang, Haiyan Cui, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 19
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
Yize Mao, Hui Xie, Min‐Yi Lv, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2483-2498
Closed Access | Times Cited: 13
LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
Ziyi He, Wei Feng, Yuxuan Wang, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 3, pp. 510-529
Open Access | Times Cited: 12
Prognostic molecular subtype reveals the heterogeneity of tumor immune microenvironment in gastric cancer
Hui Dai, Jing Ren, Chun Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
Rachael Thomas, Claire A. Wiley, Emma L. Droste, et al.
PLoS Genetics (2023) Vol. 19, Iss. 4, pp. e1010575-e1010575
Open Access | Times Cited: 10
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer
Ella Ä. Eklund, Johanna Svensson, Linda Näslund, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
DNMT3B promotes the progression of pheochromocytoma by mediating the hypermethylation of LRP1B promoter
Min Sun, Yanrong Ma, Jing Wan, et al.
Epigenetics & Chromatin (2025) Vol. 18, Iss. 1
Open Access
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Xiao Han, Xiaoyong Tang, Hui Zhu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e004952-e004952
Open Access | Times Cited: 16
Suppression of tumorigenesis in LUAD by LRP1B through regulation of the IL-6-JAK-STAT3 pathway.
Chunshui Ye, Wei Chong, Yuan Liu, et al.
PubMed (2023) Vol. 13, Iss. 7, pp. 2886-2905
Closed Access | Times Cited: 8
Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy
Jana Karolová, Dmitry Kazantsev, Michael Svatoň, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1627-1636
Open Access | Times Cited: 8
Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer
Min‐Kyue Shin, Soomin Ahn, Sun-Young Jung, et al.
Cancer Medicine (2023) Vol. 12, Iss. 18, pp. 18633-18642
Open Access | Times Cited: 8
Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer
Zhansheng Jiang, Mingyu Zhu, Lu Zhang, et al.
Gynecologic Oncology (2024) Vol. 187, pp. 1-11
Closed Access | Times Cited: 3
Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
Yoshiharu Sato
Exploration of Targeted Anti-tumor Therapy (2022), pp. 630-642
Open Access | Times Cited: 14
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
Federico Innocenti, Wancen Mu, Xueping Qu, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 4, pp. 399-409
Closed Access | Times Cited: 7
TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
Jiangyong Yu, Zaiwen Fan, Zhipeng Zhou, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3382-3382
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top